Latest News

What Matters Most in Specialty Pharmacy?
The specialty pharmacist has to balance myriad competing priorities in managing a specialty therapy regimen.
Top articles of the week on Specialty Pharmacy Times.
Top news of the week from across the health care landscape.
Understanding cellular mechanism can improve treatment of chronic inflammatory disease.
Research could lead to improved personalized therapies for acute myeloid leukemia.
Selenocompounds were able to kill up to 80% of cancer cells in mice.
Erin Hohman, PharmD, BCPS, director of Clinical Pharmacy Services at Amber Pharmacy, discusses trends in the specialty pipeline pharmacists should keep an eye on.
Specialty pharmacies need to maintain services that ensure optimal patient care and outcomes.

Features

Challenges Continue for True Patient-Centered Access
Access to oral chemotherapies is filled with challenges for providers and patients that can be significant, resulting in delayed therapy.
As with care for any chronic condition, the goals for advanced oncology therapies should be improving outcomes, containing costs, and increasing medication adherence.
As new biosimilars enter the market, pharmacies should carefully consider infrastructure, resources, and strategies for successfully integrating the products into their portfolio of offerings.
Despite initiatives that help patients maintain adherence, health care providers still need to leverage their collective resources and work together to overcome this tremendous hurdle in cancer care.

Featured Company Profile

 
MHA Specialty Pharmacy Solutions: Patient Engagement Strategies for Your Pharmacy

Videos

Erin Hohman, PharmD, BCPS, director of Clinical Pharmacy Services at Amber Pharmacy, discusses trends in the specialty pipeline pharmacists should keep an eye on.

Kevin James, RPh, MBA, vice president of payer strategy at US Bioservices, discusses the impact of Accountable Care Organizations on specialty pharmacy.

Josh Stein, CEO and co-founder of AdhereTech, discusses how technology can enhance the ability of specialty pharmacies to manage their patients' therapy regimen.

Daniel P. Kus, BS Pharm, RPh, vice president of Pharmacy Advantage, discusses the cost implications of pricey cholesterol-lowering PCSK9 inhibitors.

Previous TabNext Tab
Strategic Alliance Partners
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
HCPLive
ONCLive
Targeted Oncology
Physicians' Education Resource
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2016
Intellisphere, LLC. All Rights Reserved.
 

$vacMongoViewPlus$